Imricor Medical Systems (ASX: IMR) jumps 11% after world’s first MRI-guided ischemic VT ablation

Imricor Medical Systems Inc, listed on the Australian Securities Exchange under the ticker ASX: IMR, recorded a sharp 11.36 percent gain on November 4, 2025, following the announcement of a historic advancement in cardiac care. The American medical technology firm revealed that its products had enabled the world’s first ischemic ventricular tachycardia (VT) ablation procedure to be performed entirely under real-time magnetic resonance imaging (MRI) guidance. The operation took place at Amsterdam University Medical Centre and was hailed by clinicians and industry observers as a breakthrough moment in electrophysiology and interventional imaging.

The stock ended the session at AUD 1.52, up from the previous close of AUD 1.365, on trading volume that more than doubled its four-week average. The announcement comes as a major validation of Imricor Medical Systems’ long-standing strategy to pioneer MRI-guided cardiac ablation procedures, which are designed to replace traditional X-ray fluoroscopy with safer, more precise, and radiation-free imaging.

What made this ischemic VT ablation procedure an industry-defining first in MRI-guided cardiac intervention?

The procedure involved multiple global firsts in human cardiac electrophysiology. For the first time, a transseptal crossing from the right atrium to the left atrium was performed under real-time MRI using Imricor Medical Systems’ NavTrac-MR Transseptal Kit and Needle. Once inside the left ventricle, clinicians deployed the company’s Vision-MR Ablation Catheter 2.0 to perform mapping and ablation, guided entirely by MRI visuals rather than fluoroscopy.

This was also the first time ablation lesions were delivered from within the ventricle under MRI, and notably, the first such ablation conducted in a patient already implanted with a cardioverter-defibrillator. Historically, the presence of such devices has been considered incompatible with MRI due to interference risks, making this demonstration particularly significant. Following the procedure, the patient was found to be non-inducible for VT, which is a key clinical indicator of acute procedural success.

The operation was led by Dr. Michiel Kemme, who explained that the clarity of MRI imaging enabled the team to precisely target scar tissue caused by myocardial infarction. The result, he noted, was a level of procedural accuracy that far exceeds what conventional techniques allow. The capability to visualize anatomy in three dimensions in real time fundamentally alters how electrophysiologists navigate the heart, especially in patients with complex arrhythmias like ischemic VT.

How does this advancement align with Imricor Medical Systems’ broader clinical trial and commercial strategy?

The successful procedure represents a critical milestone in Imricor Medical Systems’ VISABL-VT clinical trial, which is currently focused on demonstrating the safety and effectiveness of MRI-guided ablations for ventricular tachycardia. The company’s product portfolio includes capital equipment such as the NorthStar Mapping System and the Advantage-MR EP Recorder and Stimulator, as well as a growing line of single-use devices including steerable sheaths, diagnostic catheters, and ablation tools—all designed to function safely within an MRI environment.

To date, the company’s devices have received regulatory approvals in the European Union, the Kingdom of Saudi Arabia, and New Zealand. Approval processes are underway in the United States through the Food and Drug Administration, with further filings in geographies such as Australia expected to follow. With the ischemic VT milestone now achieved, Imricor Medical Systems is poised to accelerate commercial adoption across hospital systems that have already begun conducting simpler ablation procedures like atrial flutter and premature ventricular complex treatments using its platform.

Steve Wedan, Chair and Chief Executive Officer of Imricor Medical Systems, described the breakthrough as a validation of the firm’s foundational vision. He noted that this milestone confirms what the company has long proposed: that real-time MRI guidance can dramatically enhance the safety, precision, and personalization of cardiac ablations. Wedan emphasized that this advancement transitions MRI-guided ablation from conceptual to real-world application, and he credited both the Amsterdam team and Imricor’s internal teams for reaching a milestone that has eluded competitors for decades.

How are investors and institutional analysts reacting to Imricor Medical Systems’ world‑first MRI‑guided VT ablation milestone on the ASX?

Imricor Medical Systems’ one-year return of 104.03 percent ranks it among the top-performing healthcare stocks on the Australian Securities Exchange. It currently holds the 35th position out of 235 in its sector, and is ranked 537th among 2,304 listed equities across the broader exchange. With a market capitalization of approximately AUD 487.62 million and more than 320 million shares issued, the company is gaining attention from both medtech-focused institutions and growth-oriented investors.

Despite posting negative earnings per share of AUD -0.212 and a price-to-earnings ratio of zero, the company’s share price appreciation suggests that the market is prioritizing its clinical pipeline and technology leadership. The daily trading volume on November 4 exceeded 436,000 shares, more than twice the 4-week average of 203,000 shares, indicating a surge in investor interest following the announcement.

Sentiment among analysts and early-stage medtech specialists appears to lean bullish, with expectations that this milestone could accelerate hospital procurement cycles and regulatory traction in high-value jurisdictions. Some observers see the success in patients with implantable defibrillators as particularly important, potentially opening access to a previously underserved segment of the EP market.

How does this development position Imricor Medical Systems in the competitive landscape of interventional cardiology?

For over two decades, clinicians and researchers have hypothesized that real-time MRI could offer a safer and more effective alternative to X-ray-based guidance in cardiac interventions. However, technical limitations, device incompatibility, and procedural risk in patients with implants have stifled widespread adoption. Imricor Medical Systems has now demonstrated that these barriers can be overcome with an integrated product suite, strong clinical partnerships, and a long-term innovation roadmap.

Electrophysiologists have long asked for imaging solutions that provide superior anatomical insight, especially for challenging cases such as ischemic VT and atrial fibrillation. These two conditions account for over 80 percent of cardiac ablations globally, representing a substantial market opportunity. The Amsterdam procedure, now part of the VISABL-VT trial, shows that MRI-guided ablation is not just viable but potentially superior in these high-risk contexts.

Hospitals aiming to reduce radiation exposure for staff and patients while increasing the success rates of complex ablations now have a compelling reason to evaluate Imricor’s platform. In particular, sites investing in interventional cardiac MRI infrastructure may view this milestone as a signal to accelerate upgrades or conversions to MRI-compatible labs.

What is the future outlook for Imricor Medical Systems as MRI-guided electrophysiology gains traction?

The global medical device sector is increasingly focused on technologies that improve safety, personalization, and procedural efficiency. With conventional VT ablations often requiring more than eight hours and delivering success rates below 50 percent, the prospect of more accurate, MRI-guided alternatives has gained traction among clinicians and administrators alike.

Imricor Medical Systems is now strategically positioned to scale its technology across Europe and potentially into the United States, pending regulatory approval. The company’s products are also gaining visibility in the Asia-Pacific region, with expected filings in Australia and growing interest among leading cardiology centers.

Over the next 12 to 18 months, the expansion of the VISABL-VT trial to additional European hospitals could serve as a bellwether for broader market adoption. Analysts are watching closely to see if this success can translate into recurring commercial contracts, particularly in regions already equipped with MRI facilities. As MRI-guided electrophysiology evolves from concept to clinical reality, Imricor Medical Systems appears poised to become a first mover in a new era of cardiac care.

What are the key takeaways from Imricor Medical Systems’ MRI-guided ischemic VT milestone and stock movement?

• Imricor Medical Systems (ASX: IMR) shares rose 11.36% on November 4, 2025, following the announcement of the world’s first MRI-guided ischemic ventricular tachycardia (VT) ablation.
• The breakthrough procedure was performed by Amsterdam University Medical Centre using Imricor Medical Systems’ MRI-compatible catheters and imaging tools.
• This marks the first successful VT ablation under real-time MRI guidance in a patient with an implanted cardioverter-defibrillator (ICD), removing a key technical barrier.
• The operation is part of the VISABL-VT clinical trial and represents a major advancement in the field of interventional cardiac electrophysiology.
• Imricor Medical Systems’ proprietary platform enabled a transseptal crossing and ablation directly within the ventricle, all guided via MRI instead of traditional X-ray fluoroscopy.
• Institutional and investor sentiment turned bullish, with trading volume doubling and the stock’s one-year return crossing 104 percent.
• Analysts view the milestone as a validation of the company’s long-term vision and a catalyst for accelerated regulatory and commercial expansion.
• With product approvals in the EU, Saudi Arabia, and New Zealand, and FDA processes underway in the United States, Imricor Medical Systems is positioned to scale its technology globally.